Mesoblast (MESO) EPS (Weighted Average and Diluted) (2017)
Mesoblast's (MESO) quarterly EPS (Weighted Average and Diluted) came in at -$211.42 in Q4 2017.
Mesoblast (MESO) EPS (Weighted Average and Diluted) (2017) Analysis & Trends
Mesoblast has disclosed EPS (Weighted Average and Diluted) across 1 years of filings, most recently posting -$211.42 for Q4 2017.
- EPS (Weighted Average and Diluted) for Q4 2017 came in at -$211.42, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was -$211.42 (changed N/A YoY), and the FY2025 annual result was -$0.08, up 5.05% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$211.42 for Q4 2017 at Mesoblast.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$211.42 in Q4 2017 to a low of -$211.42 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -211.42 |